

## **McCann Health Medical Communications Position Statement on Biomedical Publications**

McCann Health Medical Communications is composed of separate specialist agencies, some of which, under the direction of the authors, and funded by the sponsors of the research (primarily the biopharmaceutical/vaccine/medical device industry), are involved in developing biomedical publications.

The agencies within McCann Health Medical Communications advocate Good Publication Practice<sup>1</sup> and fully support the AMWA-EMWA-ISMP joint position statement on the role of professional medical writers.<sup>2</sup>

As such, we require that the work our agencies undertake in the preparation of manuscripts for peer-reviewed journals and abstracts and poster/podium presentations for congresses is conducted ethically, in line with these principles.

This means that all individuals within McCann Health Medical Communications who may be involved in both the research and preparation of biomedical publications:

1. work with authors from the outset and throughout the writing process to communicate information that is accurate, complete and objectively presented regarding the interpretation of the findings
2. apply the definition of authorship and contribution, as set out by the International Committee of Medical Journal Editors (ICMJE)<sup>3</sup> and by specific journals
3. work with authors to help facilitate timely publication of data into the peer-reviewed literature
4. adhere to reporting standards such as CONSORT<sup>4</sup> for randomised controlled studies and PRISMA<sup>5</sup> for systematic reviews
5. ensure that the contributions of individuals who do not specifically qualify for authorship, but who were involved in the development of a publication (for example, professional medical writers and/or editors), are acknowledged within it
6. adhere to journal and congress requirements to fully disclose sources of funding and, in agreement with the study sponsors and authors, to share additional requested information (for example, study protocols, study data etc.)
7. keep abreast of changes in international legislation, policies and procedures so that our working practices are in line with current biomedical publishing guidelines.

We ensure that all individuals are appropriately trained on these guidelines and are able to advise authors and research sponsors on best practices relating to biomedical publications.

McCann Health Medical Communications will **not** work on publications with clients/sponsors who:

1. veto the investigators' right to publish the findings of research or refuse to publish negative or inconclusive data into the peer-reviewed literature
2. selectively report positive endpoints rather than reporting all clinically relevant endpoints
3. overrule the interpretation of the research findings by the investigators
4. report data in a manner that is misleading or ask for marketing messages to be included
5. fail to clarify where analyses were post hoc and not pre-specified by the statistical analysis plan

- do not make it clear (via the use of clinical trial identifiers) when the publication is a follow-up from research that has already been published
- will not provide full disclosure or acknowledge professional medical writing support.

Planning is often required to ensure that publications are developed in an appropriate and timely manner. Where required, McCann Health Medical Communications can assist clients/sponsors and study groups with publication planning. The purpose of the publication planning process is to:

- ensure that authors are involved in the decision-making about when and where the data from a study are disseminated to the medical community via the peer-reviewed literature
- ensure, through the identification of appropriate congresses and journals, that individuals interested in the research and data will be able to access them within the peer-reviewed literature
- ensure that timelines allow for authors to interrogate the data fully, interpret their findings, critique and comment on drafts of the publications, and approve the final versions
- identify whether all data can be reported in a single publication or whether the number and importance of the analyses within the study will require more than one publication (and that each publication references the others to ensure that perceptions regarding the evidence base remain accurate)
- ensure that, when more than one manuscript is being developed from a data-set, the first publication reports the primary efficacy and safety/tolerability endpoints (as defined by the statistical analysis plan) of the entire data-set
- prevent redundant publications being developed and published.

## References

- Battisti WP, Wager E, Baltzer L et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. *Ann Intern Med* 2015; 163(6):461-464
- [AMWA-EMWA-ISMP joint position statement on the role of professional medical writers](#) [accessed 14 January 2019]
- International Committee of Medical Journal Editors (ICMJE). Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Available at: <http://www.icmje.org/icmje-recommendations.pdf> (updated December 2018) [accessed 14 January 2019]
- CONSORT statement. Available at: <http://www.consortstatement.org> [accessed 14 January 2019]
- PRISMA statement. Available at: <http://prisma-statement.org> [accessed 14 January 2019]

Date of Issue: 15 January 2019

Previous issue: 01 February 2017

Previous issue: 24 September 2015

Latest date of next issue: 31 January 2021